Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis

References

• Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–13. doi:10.1038/s41575-019-0189-8.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJH, Watanabe T. Colorectal cancer. Nat Rev Dis Primers. 2015;1(1):15065. doi:10.1038/nrdp.2015.65.
   PubMed Web of Science ®Google Scholar
• O’Sullivan DE, Sutherland RL, Town S, Chow K, Fan J, Forbes N, Heitman SJ, Hilsden RJ, Brenner DR. Risk factors for early-onset colorectal cancer: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(6):1229–1240.e5. doi:10.1016/j.cgh.2021.01.037.
   PubMed Web of Science ®Google Scholar
• Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338–344. doi:10.1136/gutjnl-2022-327736.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Le Naour J, Kroemer G. The ambiguous role of FPR1 in immunity and inflammation. Oncoimmunology. 2020;9(1):1760061. doi:10.1080/2162402X.2020.1760061.
   PubMed Web of Science ®Google Scholar
• Tucker EJ, Hershman SG, Kohrer C, Belcher-Timme CA, Patel J, Goldberger OA, Christodoulou J, Silberstein J, McKenzie M, Ryan M, et al. Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. Cell Metab. 2011;14(3):428–434. doi:10.1016/j.cmet.2011.07.010.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Wang L, Guo J, Sun D, Wang Y, Liu W, Xu HE, Zhang C. Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2. Nat Commun. 2022;13(1):1054. doi:10.1038/s41467-022-28586-0.
   PubMed Web of Science ®Google Scholar
• Sun R, Iribarren P, Zhang N, Zhou Y, Gong W, Cho EH, Lockett S, Chertov O, Bednar F, Rogers TJ, et al. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol. 2004;173(1):428–436. doi:10.4049/jimmunol.173.1.428.
   PubMed Web of Science ®Google Scholar
• Wang W, Li T, Wang X, Yuan W, Cheng Y, Zhang H, Xu E, Zhang Y, Shi S, Ma D, et al. FAM19A4 is a novel cytokine ligand of formyl peptide receptor 1 (FPR1) and is able to promote the migration and phagocytosis of macrophages. Cell Mol Immunol. 2015;12(5):615–624. doi:10.1038/cmi.2014.61.
   PubMed Web of Science ®Google Scholar
• Baracco EE, Stoll G, Van Endert P, Zitvogel L, Vacchelli E, Kroemer G. Contribution of annexin A1 to anticancer immunosurveillance. Oncoimmunology. 2019;8(11):e1647760. doi:10.1080/2162402X.2019.1647760.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972–978. doi:10.1126/science.aad0779.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy. Cancer Res. 2016;76(11):3122–3126. doi:10.1158/0008-5472.CAN-16-0294.
   PubMed Web of Science ®Google Scholar
• Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1). Oncoimmunology. 2021;10(1):1926074. doi:10.1080/2162402X.2021.1926074.
   PubMed Web of Science ®Google Scholar
• Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother. 2021;70(10):2937–2950. doi:10.1007/s00262-021-02894-8.
   PubMed Web of Science ®Google Scholar
• Carbonnier V, Le Naour J, Bachelot T, Vacchelli E, Andre F, Delaloge S, Kroemer G. Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer. Oncoimmunology. 2023;12(1):2189823. doi:10.1080/2162402X.2023.2189823.
   PubMed Web of Science ®Google Scholar
• Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre C-A, Ginhoux F, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. 2021;11(2):408–423. doi:10.1158/2159-8290.CD-20-0465.
   PubMed Web of Science ®Google Scholar
• Sztupinszki Z, Le Naour J, Vacchelli E, Laurent-Puig P, Delaloge S, Szallasi Z, Kroemer G. A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncoimmunology. 2021;10(1):1859064. doi:10.1080/2162402X.2020.1859064.
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology. 2013;2(6):e24568. doi:10.4161/onci.24568.
   PubMed Web of Science ®Google Scholar
• Angelou A, Andreatos N, Antoniou E, Zacharioudaki A, Theodoropoulos G, Damaskos C, Garmpis N, Yuan C, Xiao W, Theocharis S, et al. A novel modification of the AOM/DSS model for inducing intestinal adenomas in mice. Anticancer Res. 2018;38(6):3467–3470. doi:10.21873/anticanres.12616.
   PubMed Web of Science ®Google Scholar
• Parang B, Barrett CW, Williams CS. AOM/DSS model of colitis-associated cancer. Methods Mol Biol. 2016;1422:297–307.
   PubMedGoogle Scholar
• Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE, Philpott DJ, et al. Comparison of co-housing and littermate methods for microbiota standardization in mouse models. Cell Rep. 2019;27(6):1910–1919.e2. doi:10.1016/j.celrep.2019.04.023.
   PubMed Web of Science ®Google Scholar
• Li SQ, Su N, Gong P, Zhang HB, Liu J, Wang D, Sun Y-P, Zhang Y, Qian F, Zhao B, et al. The expression of formyl peptide receptor 1 is correlated with tumor invasion of human colorectal cancer. Sci Rep. 2017;7(1):5918. doi:10.1038/s41598-017-06368-9.
   PubMedGoogle Scholar
• Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer. 1995;31(7–8):1061–1064. doi:10.1016/0959-8049(95)00181-H.
   Google Scholar
• Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256(5057):668–670. doi:10.1126/science.1350108.
   PubMed Web of Science ®Google Scholar
• Fletcher R, Tong J, Risnik D, Leibowitz BJ, Wang YJ, Concha-Benavente F, DeLiberty JM, Stolz DB, Pai RK, Ferris RL, et al. Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis. Oncogene. 2021;40(11):2035–2050. doi:10.1038/s41388-021-01687-8.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht DB, Rigas B, Shiff SJ. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene. 1996;12:893–901.
   PubMed Web of Science ®Google Scholar
• Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001;2:677–683.
   PubMedGoogle Scholar
• Lee HJ, Wang XN, Shi DL, Zheng JJ. Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. Angew Chem Int Ed Engl. 2009;48(35):6448–6452. doi:10.1002/anie.200902981.
   PubMed Web of Science ®Google Scholar
• Oldekamp S, Pscheidl S, Kress E, Soehnlein O, Jansen S, Pufe T, Wang JM, Tauber SC, Brandenburg L-O. Lack of formyl peptide receptor 1 and 2 leads to more severe inflammation and higher mortality in mice with of pneumococcal meningitis. Immunology. 2014;143(3):447–461. doi:10.1111/imm.12324.
   PubMed Web of Science ®Google Scholar
• Zhang M, Gao JL, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM, et al. A critical role of formyl peptide receptors in host defense against Escherichia coli. J Immunol. 2020;204(9):2464–2473. doi:10.4049/jimmunol.1900430.
   PubMed Web of Science ®Google Scholar
• Osei-Owusu P, Charlton TM, Kim HK, Missiakas D, Schneewind O. FPR1 is the plague receptor on host immune cells. Nature. 2019;574(7776):57–62. doi:10.1038/s41586-019-1570-z.
   PubMed Web of Science ®Google Scholar
• Giebeler A, Streetz KL, Soehnlein O, Neumann U, Wang JM, Brandenburg LO, Mukhopadhyay P. Deficiency of formyl peptide receptor 1 and 2 is associated with increased inflammation and enhanced liver injury after LPS-stimulation. PLoS One. 2014;9(6):e100522. doi:10.1371/journal.pone.0100522.
   PubMed Web of Science ®Google Scholar
• Bihler K, Kress E, Esser S, Nyamoya S, Tauber SC, Clarner T, Stope MB, Pufe T, Brandenburg L-O. Formyl peptide receptor 1-mediated glial cell activation in a mouse model of cuprizone-induced demyelination. J Mol Neurosci. 2017;62(2):232–243. doi:10.1007/s12031-017-0924-y.
   PubMed Web of Science ®Google Scholar
• Fusco R, Gugliandolo E, Siracusa R, Scuto M, Cordaro M, D’Amico R, Evangelista M, Peli A, Peritore AF, Impellizzeri D, et al. Formyl peptide receptor 1 signaling in acute inflammation and neural differentiation induced by traumatic brain injury. Biology (Basel). 2020;9(9):238. doi:10.3390/biology9090238.
   PubMedGoogle Scholar
• Li J, Chordia MD, Zhang Y, Zong H, Pan D, Zuo Z. Critical role of FPR1 in splenocyte migration into brain to worsen inflammation and ischemic brain injury in mice. Theranostics. 2022;12(7):3024–3044. doi:10.7150/thno.57218.
   PubMed Web of Science ®Google Scholar
• Grommes J, Drechsler M, Soehnlein O. CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. J Innate Immun. 2014;6(1):111–116. doi:10.1159/000353229.
   PubMed Web of Science ®Google Scholar
• Yuan ZC, Zeng N, Liu L, Wang T, Dai LQ, Wang H, Zeng Z-J, Cao Y-F, Zhou Y-F, Xu D, et al. Mitochondrial damage-associated molecular patterns exacerbate lung fluid imbalance via the formyl peptide receptor-1 signaling pathway in acute lung injury. Crit Care Med. 2021;49(1):e53–e62. doi:10.1097/CCM.0000000000004732.
   PubMed Web of Science ®Google Scholar
• Cardini S, Dalli J, Fineschi S, Perretti M, Lungarella G, Lucattelli M. Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am J Respir Cell Mol Biol. 2012;47(3):332–339. doi:10.1165/rcmb.2012-0036OC.
   PubMed Web of Science ®Google Scholar
• Gao L, Zeng N, Yuan Z, Wang T, Chen L, Yang D, Xu D, Wan C, Wen F, Shen Y, et al. Knockout of formyl peptide receptor-1 attenuates cigarette smoke–induced airway inflammation in mice. Front Pharmacol. 2021;12:632225. doi:10.3389/fphar.2021.632225.
   PubMed Web of Science ®Google Scholar
• Leslie J, Millar BJ, Del Carpio Pons A, Burgoyne RA, Frost JD, Barksby BS, Luli S, Scott J, Simpson AJ, Gauldie J, et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight. 2020;5(4). doi:10.1172/jci.insight.125937.
   PubMed Web of Science ®Google Scholar
• D’Amico R, Fusco R, Cordaro M, Siracusa R, Peritore AF, Gugliandolo E, Crupi R, Scuto M, Cuzzocrea S, Di Paola R, et al. Modulation of NLRP3 inflammasome through Formyl Peptide Receptor 1 (Fpr-1) pathway as a new therapeutic target in bronchiolitis obliterans syndrome. Int J Mol Sci. 2020;21(6):21. doi:10.3390/ijms21062144.
   Web of Science ®Google Scholar
• Alam A, Leoni G, Wentworth CC, Kwal JM, Wu H, Ardita CS, Swanson PA, Lambeth JD, Jones RM, Nusrat A, et al. Redox signaling regulates commensal-mediated mucosal homeostasis and restitution and requires formyl peptide receptor 1. Mucosal Immunol. 2014;7(3):645–655. doi:10.1038/mi.2013.84.
   PubMed Web of Science ®Google Scholar
• Farooq SM, Stadnyk AW. Neutrophil infiltration of the colon is independent of the FPR1 yet FPR1 deficient mice show differential susceptibilities to acute versus chronic induced colitis. Dig Dis Sci. 2012;57(7):1802–1812. doi:10.1007/s10620-012-2082-y.
   PubMed Web of Science ®Google Scholar
• Di Paola R, Fusco R, Gugliandolo E, D’Amico R, Cordaro M, Impellizzeri D, Perretti M, Cuzzocrea S. Formyl peptide receptor 1 signalling promotes experimental colitis in mice. Pharmacol Res. 2019;141:591–601. doi:10.1016/j.phrs.2019.01.041.
   PubMed Web of Science ®Google Scholar
• Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2(8):1998–2004. doi:10.1038/nprot.2007.279.
   PubMed Web of Science ®Google Scholar
• Wollam J, Riopel M, Xu YJ, Johnson AMF, Ofrecio JM, Ying W, El Ouarrat D, Chan LS, Han AW, Mahmood NA, et al. Microbiota-produced N-Formyl peptide fMLF promotes obesity-induced glucose intolerance. Diabetes. 2019;68(7):1415–1426. doi:10.2337/db18-1307.
   PubMed Web of Science ®Google Scholar
• Terasaki M, Uehara O, Ogasa S, Sano T, Kubota A, Kojima H, Tanaka T, Maeda H, Miyashita K, Mutoh M, et al. Alteration of fecal microbiota by fucoxanthin results in prevention of colorectal cancer in AOM/DSS mice. Carcinogenesis. 2021;42(2):210–219. doi:10.1093/carcin/bgaa100.
   PubMed Web of Science ®Google Scholar
• Molloy MJ, Grainger JR, Bouladoux N, Hand TW, Koo LY, Naik S, Quinones M, Dzutsev A, Gao J-L, Trinchieri G, et al. Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. Cell Host & Microbe. 2013;14(3):318–328. doi:10.1016/j.chom.2013.08.003.
   PubMed Web of Science ®Google Scholar
• Alam A, Leoni G, Quiros M, Wu H, Desai C, Nishio H, Jones RM, Nusrat A, Neish AS. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. Nat microbiol. 2016;1(2):15021. doi:10.1038/nmicrobiol.2015.21.
   PubMed Web of Science ®Google Scholar
• Wang F, Cai K, Xiao Q, He L, Xie L, Liu Z. Akkermansia muciniphila administration exacerbated the development of colitis-associated colorectal cancer in mice. J Cancer. 2022;13(1):124–133. doi:10.7150/jca.63578.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, Yuan G, Zhu J, Cao S, Wu Q, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8 + T cells in mice. Gut. 2020;69(11):1988–1997. doi:10.1136/gutjnl-2019-320105.
   PubMed Web of Science ®Google Scholar
• Chandrasekharan B, Saeedi BJ, Alam A, Houser M, Srinivasan S, Tansey M, Jones R, Nusrat A, Neish AS. Interactions between commensal bacteria and enteric neurons, via FPR1 induction of ROS, increase gastrointestinal motility in mice. Gastroenterology. 2019;157(1):179–192.e2. doi:10.1053/j.gastro.2019.03.045.
   PubMed Web of Science ®Google Scholar
• Hattori N, Niwa T, Ishida T, Kobayashi K, Imai T, Mori A, Kimura K, Mori T, Asami Y, Ushijima T, et al. Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model. Cancer Sci. 2019;110:147–156. doi:10.1111/cas.13880.
   PubMed Web of Science ®Google Scholar
• Lee JG, Eun CS, Jo SV, Lee AR, Park CH, Han DS, Nakano H. The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model. PLoS One. 2019;14(12):e0226907. doi:10.1371/journal.pone.0226907.
   PubMed Web of Science ®Google Scholar
• Xu H, Hiraishi K, Kurahara LH, Nakano-Narusawa Y, Li X, Hu Y, Matsuda Y, Zhang H, Hirano K. Inhibitory effects of breast milk-derived lactobacillus rhamnosus Probio-M9 on colitis-associated carcinogenesis by restoration of the gut microbiota in a mouse model. Nutrients. 2021;13(4):1143. doi:10.3390/nu13041143.
   PubMed Web of Science ®Google Scholar
• Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology. 2018;7(9):e1462431. doi:10.1080/2162402X.2018.1462431.
   PubMed Web of Science ®Google Scholar
• Le Naour J, Montegut L, Joseph A, Garbin K, Vacchelli E, Kroemer G, Pol JG, Maiuri MC. Improved Swiss-rolling method for histological analyses of colon tissue. MethodsX. 2022;9:101630. doi:10.1016/j.mex.2022.101630.
   PubMed Web of Science ®Google Scholar
• Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. doi:10.1038/s41598-017-17204-5.
   PubMedGoogle Scholar
• Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology. 2003;124(3):762–777. doi:10.1053/gast.2003.50094.
   PubMed Web of Science ®Google Scholar
• Nolte T, Brander-Weber P, Dangler C, Deschl U, Elwell MR, Greaves P, Hailey R, Leach MW, Pandiri AR, Rogers A, et al. Nonproliferative and proliferative lesions of the gastrointestinal tract, pancreas and salivary glands of the rat and mouse. J Toxicol Pathol. 2016;29(1_Suppl):1S–125S. doi:10.1293/tox.29.1S.
   PubMed Web of Science ®Google Scholar
• Ward JM, Treuting PM. Rodent intestinal epithelial carcinogenesis: pathology and preclinical models. Toxicol Pathol. 2014;42(1):148–161. doi:10.1177/0192623313505156.
   PubMed Web of Science ®Google Scholar
• Angelakis E, Bachar D, Henrissat B, Armougom F, Audoly G, Lagier JC, Robert C, Raoult D. Glycans affect DNA extraction and induce substantial differences in gut metagenomic studies. Sci Rep. 2016;6(1):26276. doi:10.1038/srep26276.
   PubMedGoogle Scholar
• Boudreau J, Koshy S, Cummings D, Wan Y. Culture of myeloid dendritic cells from bone marrow precursors. J Vis Exp. 2008;17. doi:10.3791/769-v.
   PubMedGoogle Scholar